HANSA MEDICAL AB ORD overview

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance PR Newswire LUND, Sweden, April 2, 2024 Company expects revenue of SEK 54m including product sales of SEK 48m - an increase of 10% versus the prior quarter and a 234% increase versus Q1 2023 Q1 2024 is the first time Hansa has delivered two consecutive quarters of strong revenue and growth LUND, Sweden , April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending...

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance PR Newswire LUND, Sweden, April 2, 2024 Company expects revenue of SEK 54m including product sales of SEK 48m - an increase of 10% versus the prior quarter and a 234% increase versus Q1 2023 Q1 2024 is the first time Hansa has delivered two consecutive quarters of strong revenue and growth LUND, Sweden , April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending...

Hansa Biopharma publishes 2023 Annual and Sustainability Reports PR Newswire LUND, Sweden, March 21, 2024 Company delivered significant progress across commercial and R&D priorities LUND, Sweden , March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a...

Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer PR Newswire LUND, Sweden, Feb. 22, 2024 LUND, Sweden , Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024 . He succeeds Donato Spota , who, as previously announced, will leave the Company on 28 February. As CFO, Mr. Ballantyne will be responsible for developing and implementing the Company's...

Hansa Biopharma Year-end report January-December 2023 PR Newswire LUND, Sweden, Feb. 2, 2024 Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany , and Spain Encouraging results from first-in-human trial of HNSA-5487 Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta's SRP-9001 in DMD LUND, Sweden , Feb. 2, 2024 /PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme...

Hansa Biopharma Year-end report January-December 2023 PR Newswire LUND, Sweden, Feb. 2, 2024 Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany , and Spain Encouraging results from first-in-human trial of HNSA-5487 Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta's SRP-9001 in DMD LUND, Sweden , Feb. 2, 2024 /PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme...

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference PR Newswire LUND, Sweden, Jan. 6, 2024 Strong revenue generation in Q4 2023, including SEK 43m in Idefirix ® product sales supported by growth in new markets such as U.K., Germany , and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa's lead candidate from the NiceR program for repeat dosing Initiation of phase 1b trial of imlifidase as pre-treatment to...

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference PR Newswire LUND, Sweden, Jan. 6, 2024 Strong revenue generation in Q4 2023, including SEK 43m in Idefirix ® product sales supported by growth in new markets such as U.K., Germany , and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa's lead candidate from the NiceR program for repeat dosing Initiation of phase 1b trial of imlifidase as pre-treatment to...